InterStim Therapy System, Verify Evaluation System (SNS Urinary Neurostimulator 97800), (SNS Urinary Neurostimulator I
Medtronic Neuromodulation · Decision date Oct 29, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-10-29 for PMA supplement P970004/S460, submitted by Medtronic Neuromodulation as a 30-Day Notice for a process change affecting manufacturing, sterilization, packaging or supplier operations. The supplement sits under P970004, whose listed title covers the InterStim Therapy System and Verify Evaluation System, including the SNS Urinary Neurostimulator 97800. The device category is an electrical implantable stimulator for incontinence, with gastroenterology and urology specialties and product code EZW.
The recorded statement describes battery-line process controls rather than a new approval of the whole system: enhanced operator verification of the FactoryWorks step and recorded battery pre-weight, pre- and post-weight out-of-control action plans, software and human machine interface updates that reject batteries above the established final-fill reasonable limit, dedicated white work-in-progress trays, an isopropyl alcohol wipe for residual electrolyte, and removal of Ball Press and Button Press certification prerequisites for ram changes on Medium Rate Line 2, with supervisors and engineers retaining certification responsibility. No documents were provided, so the underlying supplement filing and any clinical or labeling effect remain unknown.
The listed date is in the future relative to typical publication timelines, and the source does not state whether the notice was accepted without further review or what follow-up applies. Whether these manufacturing changes alter device performance or labeling cannot be determined from the record.
FDA approval order statement
1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 29, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P970004/S460
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Neuromodulation
- Product code
- EZW
- Decision code
- OK30
- Decision date
- Oct 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implantable, for incontinence.
- Applicant
- Medtronic Neuromodulation
- Product code
- EZW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P970004. Subsequent supplements may change the device or its indications.
FDA decision timeline
P970004 · Original PMA
MEDTRONIC INTERSTIM THERAPY SYSTEM FOR URINARY CONTROL
P970004/S458 · Related supplement
InterStim Therapy System Verify Evaluation System
P970004/S460 received
Application receipt date recorded by FDA.
P970004/S457 · Related supplement
InterStim Therapy System, Verify Evaluation System
P970004/S459 · Related supplement
InterStim Therapy System, Verify Evaluation System
P970004/S460 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P970004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P970004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA approval | Sep 29, 1997 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Sep 14, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 9, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Neuromodulation
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P970004/S460
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

